Erratum: Novel therapeutics for the treatment of familial mediterranean fever: From colchicine to biologics (Clinical Pharmacology and Therapeutics (2013) DOI: 10.1038/clpt.2013.148);Novel therapeutics for the treatment of familial mediterranean fever: From colchicine to biologics

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 1, 2014, Pages 89-97

  Grattagliano, I ^a,e   Bonfrate, L ^b   Ruggiero, V ^b   Scaccianoce, G ^b,c   Palasciano, G ^b   Portincasa, P ^b,d  

^a Italian College of General Practitioners   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c Umberto I Hospital   (Italy)

^d European Society for Clinical Investigation (ESCI)   (Netherlands)

^e Florence and Bari   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; COLCHICINE; DAPSONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; ARTICLE; AUTOINFLAMMATORY DISEASE; CLINICAL FEATURE; FAMILIAL MEDITERRANEAN FEVER; HUMAN; INFECTION PREVENTION; INFLAMMATION; KIDNEY AMYLOIDOSIS; MOUTH LESION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DEFECT; TREATMENT OUTCOME;

EID: 84890973444     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.213     Document Type: Erratum

References (79)

1. Ben-Chetrit, E. & Levy, M. Familial Mediterranean fever. Lancet 351, 659-664 (1998). (Pubitemid 28098460)
2. Ben-Chetrit, E. & Touitou, I. Familial Mediterranean fever in the world. Arthritis Rheum. 61, 1447-1453 (2009).
3. Drenth, J.P. & van der Meer, J.W. Hereditary periodic fever. N. Engl. J. Med. 345, 1748-1757 (2001).
4. Goldfinger, S.E. Colchicine for familial Mediterranean fever. N. Engl. J. Med. 287, 1302 (1972).
5. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 90, 797-807 (1997).
6. Berdeli, A. et al. Comprehensive analysis of a large-scale screen for MEFV gene mutations: do they truly provide a "heterozygote advantage" in Turkey? Genet. Test. Mol. Biomarkers 15, 475-482 (2011).
7. Masters, S.L., Simon, A., Aksentijevich, I. & Kastner, D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668 (2009).
8. Stehlik, C. & Reed, J.C. The PYRIN connection: novel players in innate immunity and inflammation. J. Exp. Med. 200, 551-558 (2004). (Pubitemid 39258304)
9. Richards, N. et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J. Biol. Chem. 276, 39320-39329 (2001).
10. Livneh, A. et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 6, 1-6 (1999). (Pubitemid 29249929)
11. Kone, P.I. et al. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford). 39, 1275-1279 (2000).
12. Livneh, A. et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 40, 1879-1885 (1997). (Pubitemid 27452541)
13. van der Hilst, J.C., Simon, A. & Drenth, J.P. Hereditary periodic fever and reactive amyloidosis. Clin. Exp. Med. 5, 87-98 (2005). (Pubitemid 41597267)
14. Sohar, E., Gafni, J., Pras, M. & Heller, H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am. J. Med. 43, 227-253 (1967).
15. Sungur, C. et al. Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int. 44, 834-836 (1993). (Pubitemid 23290525)
16. Heller, H., Sohar, E. & Sherf, L. Familial Mediterranean fever. AMA Arch. Intern. Med. 102, 50-71 (1958).
17. Infevers: an online database for autoinflammatory mutations. .
18. Milhavet, F. et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum. Mutat. 29, 803-808 (2008). (Pubitemid 351794131)
19. Touitou, I. et al. Infevers: an evolving mutation database for autoinflammatory syndromes. Hum. Mutat. 24, 194-198 (2004). (Pubitemid 39095595)
20. Sarrauste de Menthière, C., Terrière, S., Pugnère, D., Ruiz, M., Demaille, J. & Touitou, I. Infevers: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res. 31, 282-285 (2012).
21. Molad, Y. Update on colchicine and its mechanism of action. Curr. Rheumatol. Rep. 4, 252-256 (2002).
22. Shelanski, M.L. & Taylor, E.W. Properties of the protein subunit of central-pair and outer-doublet microtubules of sea urchin flagella. J. Cell Biol. 38, 304-315 (1968).
23. Pope, R.M. & Tschopp, J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 56, 3183-3188 (2007). (Pubitemid 47585412)
24. Gaudry, M., Roberge, C.J., de Médicis, R., Lussier, A., Poubelle, P.E. & Naccache, P.H. Crystal-induced neutrophil activation. III. Inflammatory microcrystals induce a distinct pattern of tyrosine phosphorylation in human neutrophils. J. Clin. Invest. 91, 1649-1655 (1993). (Pubitemid 23127369)
25. Cerquaglia, C., Diaco, M., Nucera, G., La Regina, M., Montalto, M. & Manna, R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr. Drug Targets. Inflamm. Allergy 4, 117-124 (2005). (Pubitemid 40584862)
26. Ferron, G.M., Rochdi, M., Jusko, W.J. & Scherrmann, J.M. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36, 874-883 (1996). (Pubitemid 26384476)
27. Wallace, S.L. & Ertel, N.H. Plasma levels of colchicine after oral administration of a single dose. Metab. Clin. Exp. 22, 749-753 (1973).
28. Bourdon, R. & Galliot, M. [Determination of colchicine in biological fluids]. Ann. Biol. Clin. (Paris) 34, 393-401 (1976).
29. Cocco, G., Chu, D.C. & Pandolfi, S. Colchicine in clinical medicine. A guide for internists. Eur. J. Intern. Med. 21, 503-508 (2010).
30. Dinarello, C.A., Wolff, S.M., Goldfinger, S.E., Dale, D.C. & Alling, D.W. Colchicine therapy for familial mediterranean fever. A double-blind trial. N. Engl. J. Med. 291, 934-937 (1974).
31. Ben-Chetrit, E. & Levy, M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin. Arthritis Rheum. 20, 241-246 (1991).
32. Kallinich, T. et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119, e474-e483 (2007). (Pubitemid 46397797)
33. Livneh, A., Zemer, D., Siegal, B., Laor, A., Sohar, E. & Pras, M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 60, 418-422 (1992).
34. Terkeltaub, R.A. Colchicine update: 2008. Semin. Arthritis Rheum. 38, 411-419 (2009).
35. Ben-Chetrit, E. & Levy, M. Colchicine: 1998 update. Semin. Arthritis Rheum. 28, 48-59 (1998). (Pubitemid 28378084)
36. Baud, F.J. et al. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N. Engl. J. Med. 332, 642-645 (1995).
37. Putterman, C., Ben-Chetrit, E., Caraco, Y. & Levy, M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin. Arthritis Rheum. 21, 143-155 (1991).
38. Ben-Chetrit, E. & Ozdogan, H. Non-response to colchicine in FMF-definition, causes and suggested solutions. Clin. Exp. Rheumatol. 26, S49-S51 (2008).
39. Portincasa, P. et al. Impaired gastrointestinal motorfunction in patients with familial mediterranean fever. Eur. J. Clin. Invest. 42, 87-87 (2012).
40. Portincasa, P. et al. Genotypical/phenotypical characterization of a novel cluster of patients with familial Mediterranean fever (FMF) in Apulia and Lucania in Southern Italy. Eur. J. Clin. Invest. 43, 72 (2013).
41. Tufan, A. et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J. Rheumatol. 34, 1540-1544 (2007). (Pubitemid 47067992)
42. Lidar, M., Kedem, R., Langevitz, P., Pras, M. & Livneh, A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J. Rheumatol. 30, 2620-2623 (2003). (Pubitemid 37549339)
43. Chae, J.J. et al. Gain-of-function Pyrin mutations induce NLRP3 proteinindependent interleukin-1ß activation and severe autoinflammation in mice. Immunity 34, 755-768 (2011).
44. Meinzer, U., Quartier, P., Alexandra, J.F., Hentgen, V., Retornaz, F. & Koné-Paut, I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin. Arthritis Rheum. 41, 265-271 (2011).
45. Mitroulis, I., Skendros, P. & Ritis, K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur. J. Intern. Med. 21, 157-163 (2010).
46. Chae, J.J. et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. USA 103, 9982-9987 (2006). (Pubitemid 43993609)
47. Kuijk, L.M., Govers, A.M., Frenkel, J. & Hofhuis, W.J. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann. Rheum. Dis. 66, 1545-1546 (2007). (Pubitemid 350032672)
48. Soriano, A., Verecchia, E., Afeltra, A., Landolfi, R. & Manna, R. IL-1ß biological treatment of familial Mediterranean fever. Clin. Rev. Allergy Immunol. 45, 117-130 (2013).
49. Petropoulou, A.D., Robin, M., Socié, G. & Galicier, L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation 90, 102-103 (2010).
50. Mitroulis, I., Papadopoulos, V.P., Konstantinidis, T. & Ritis, K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth. J. Med. 66, 489-491 (2008).
51. Moser, C. et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol. Dial. Transplant. 24, 676-678 (2009).
52. Bilginer, Y., Ayaz, N.A. & Ozen, S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin. Rheumatol. 29, 209-210 (2010).
53. Hennig, S., Bayegan, K., Uffmann, M., Thalhammer, F. & Winkler, S. Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review. Rheumatol. Int. 32, 1801-1804 (2012).
54. Belkhir, R., Moulonguet-Doleris, L., Hachulla, E., Prinseau, J., Baglin, A. & Hanslik, T. Treatment of familial Mediterranean fever with anakinra. Ann. Intern. Med. 146, 825-826 (2007). (Pubitemid 351650515)
55. Roldan, R., Ruiz, A.M., Miranda, M.D. & Collantes, E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint. Bone. Spine 75, 504-505 (2008).
56. Calligaris, L., Marchetti, F., Tommasini, A. & Ventura, A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur. J. Pediatr. 167, 695-696 (2008). (Pubitemid 351503491)
57. Alpay, N., Sumnu, A., Caliskan, Y., Yazici, H., Türkmen, A. & Gül, A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol. Int. 32, 3277-3279 (2012).
58. Ozen, S., Bilginer, Y., Aktay Ayaz, N. & Calguneri, M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J. Rheumatol. 38, 516-518 (2011).
59. Stankovic Stojanovic, K. et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol. Dial. Transplant. 27, 1898-1901 (2012).
60. Gattringer, R. et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur. J. Clin. Invest. 37, 912-914 (2007). (Pubitemid 350029205)
61. Economides, A.N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47-52 (2003). (Pubitemid 36098259)
62. Hashkes, P.J. et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann. Intern. Med. 157, 533-541 (2012).
63. Alten, R. et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10, R67 (2008).
64. Mitroulis, I., Skendros, P., Oikonomou, A., Tzioufas, A.G. & Ritis, K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann. Rheum. Dis. 70, 1347-1348 (2011).
65. Hacihamdioglu, D.O. & Ozen, S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology (Oxford). 51, 1041 (2012).
66. Ryan, J.G. et al. Clinical features and functional significance of the P369S/ R408Q variant in pyrin, the familial Mediterranean fever protein. Ann. Rheum. Dis. 69, 1383-1388 (2010).
67. Bilgen, S.A. et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J. Clin. Rheumatol. 17, 358-362 (2011).
68. Akgul, O., Kilic, E., Kilic, G. & Ozgocmen, S. Efficacy and safety of biologic treatments in familial mediterranean Fever. Am. J. Med. Sci. 346, 137-141 (2013).
69. Debol, S.M., Herron, M.J. & Nelson, R.D. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J. Leukoc. Biol. 62, 827-836 (1997). (Pubitemid 28015631)
70. Salehzadeh, F., Jahangiri, S. & Mohammadi, E. Dapsone as an alternative therapy in children with familial mediterranean Fever. Iran. J. Pediatr. 22, 23-27 (2012).
71. Tunca, M. et al.; Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 84, 1-11 (2005). (Pubitemid 40130180)
72. Cattan, D., Notarnicola, C., Molinari, N. & Touitou, I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 355, 378-379 (2000).
73. Daniels, M., Shohat, T., Brenner-Ullman, A. & Shohat, M. Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish populations in Israel. Am. J. Med. Genet. 55, 311-314 (1995).
74. Gershoni-Baruch, R., Brik, R., Shinawi, M. & Livneh, A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur. J. Hum. Genet. 10, 145-149 (2002). (Pubitemid 34414051)
75. Rogers, D.B. et al. Familial Mediterranean fever in Armenians: autosomal recessive inheritance with high gene frequency. Am. J. Med. Genet. 34, 168-172 (1989). (Pubitemid 19257629)
76. Torosyan, L., Aksentijevich, I. & Sarkisian, T. A population based survey reveals an extremely high FMF carrier frequency in Armenia suggesting heterozygote advantage. Am. J. Hum. Genet. 67, A2275 (2000).
77. Yilmaz, E. et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur. J. Hum. Genet. 9, 553-555 (2001). (Pubitemid 32750497)
78. Zemer, D., Pras, M., Sohar, E., Modan, M., Cabili, S. & Gafni, J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N. Engl. J. Med. 314, 1001-1005 (1986). (Pubitemid 16138694)
79. Tweezer-Zaks, N., Rabinovich, E., Lidar, M. & Livneh, A. Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever. J. Rheumatol. 35, 1362-1365 (2008). (Pubitemid 352000785)